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Objective. In a randomized trial ofwomenwith early stage breast cancer undergoing adjuvant chemotherapy, two stressmanagement
interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial
functioning, quality of life (QOL), and biological markers thought to reflect cancer- and treatment-specific mechanisms.Method.
The sample consisted of 145 women aged 27–75 years; 75% were Caucasian and 25% African American. A total of 109 participants
completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis
was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress-
related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the
sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy.Conclusions.
Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes.
Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced
during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have
enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy.
1. Introduction
A growing body of research with persons having chronic
and potentially fatal illnesses such as cancer indicates that
a variety of complementary or “mind-body” interventions,
including strategies for stress management, can not only
mitigate psychological distress and improve coping skills,
but also enhance immune function through neuroendocrine-
immune system modulation [1]. Briefly, PNI is concerned
with the mechanisms of multidimensional psychobehav-
ioral neuroendocrine-immune system interactions. Funda-
mental mechanisms involve (a) the hypothalamic-pituitary-
adrenocortical (HPA) system, which coordinates the release
of corticotropin (ACTH), endorphins, and glucocorticoids;
(b) the sympathetic nervous system via direct innervation
of immune cell receptors for neurotransmitters; and (c) the
sympathetic-adrenomedullary (SAM) system, which coordi-
nates the release of catecholamines and enkephalins [2].
Serious physical illnesses such as cancer are major stres-
sors that tend to bring about negative affective states. Glaser
and Keicolt-Glaser [3] summarized convincing evidence that
both psychological stress and negative emotions augment
the production of proinflammatory cytokines, concluding
that these stress-related changes thus have broad implications
for health. Virtually all stressors, both psychological and
physiological, are associated with immune activation and
enhanced production of proinflammatory cytokines such
as tumor-necrosis-factor-alpha (TNF-𝛼), interleukin-1beta
(IL-1𝛽), and IL-6 [4, 5]. Other PNI-based mechanisms
of increasing interest include endorphins and enkephalins,
given mounting evidence that these opioid peptides have
the desired response of downregulating neuroendocrine and
2 Evidence-Based Complementary and Alternative Medicine
8–10
week
postop
Study design
Chemotherapy
(8–12) weeks
10-week TCHI
or SPRT
intervention (Ix)
Data collection:
pre-Ix
month = 0
Post-Ix
3
F/U 1
4.5
F/U 2
6
Figure 1: Study design.
autonomic stress responses andmay counteract some aspects
of cortisol-induced immunosuppression [6–8].
More women are living longer with breast cancer, which
raises concerns for the quality of life of those women at
diagnosis, during treatment, and beyond. The treatment
period is known to be a highly stressful time for the growing
population of breast cancer survivors, both psychologically
and physiologically [9–11]. Women with breast cancer com-
prise the largest group of cancer survivors in the USA,
and most are relatively young at the time of diagnosis [12],
which underscores the importance of identifying strategies to
enhance health and QOL in survivorship.
2. Methods
Following informed consent and eligibility screening, partici-
pants were randomized using a computer generated random-
ization table, to enter the next scheduled 10-week treatment
group (TCHI or SPRT) or the usual care control group. As
depicted in Figure 1, data were collected at preintervention,
prior to the initiation of chemotherapy (preintervention (Pre-
Ix)), within a week following the intervention (postinter-
vention (Post-Ix)), at 4.5 months (followup 1 (F/U 1)) and
6 months after enrollment (followup 2 (F/U 2)), and at
comparable times for usual care control group participants.
Using a broad psychoneuroimmunology (PNI) frame-
work [13] to examine multiple aspects of potential stress-
related mechanisms, we evaluated the effects of 10-week
interventions of tai chi training (TCHI) or spiritual growth
groups (SPRT) in comparison to a usual care control group
among women receiving adjuvant chemotherapy for stages
I–IIIA breast cancer. We tested effects of these interven-
tions on (a) enhancing psychological well-being (perceived
stress, quality of life (QOL), and depressive symptoms), (b)
normalizing levels of stress-related neuroendocrine media-
tors (endogenous opioids), and (c) attenuating immunosup-
pression (cytokine patterns). Previous studies using these
somewhat novel interventions in persons with HIV infec-
tion documented selected psychosocial and physiological
effects including enhanced QOL, increased plasma levels
of interferon-gamma (IFN-𝛾), and increased lymphocyte
proliferative function [14, 15]. In order to expand the
application of these interventions among populations with
immune-mediated or immune-moderated conditions, we
sought to test the effects of these PNI-based approaches
for women receiving adjuvant chemotherapy for early stage
breast cancer.
2.1. Measures
2.1.1. Psychosocial Instruments. Perceived stress related to
diagnosis and treatment for breast cancer will bemeasured by
the Impact of Events Scale (IES) [16]. Because of its specific
nature and previous sensitivity to psychosocial interventions,
we used the IES to measure the subjective distress of living
with breast cancer. The IES has excellent psychometric
properties and is not confounded with physical symptoms. It
is a 15-item instrument with response options that indicate
how frequently within the past 7 days each distressing
thought related to having breast cancer and chemotherapy
has occurred. Higher scores on the subscales of intrusive and
avoidant thinking indicate greater psychological distress.
General QOL, along with QOL specific to living with
breast cancer, was measured by the Functional Assessment
of Cancer Therapy-Breast (FACT-B) cancer instrument [17].
The FACT-B (version 4) is a 44-item self-report instrument
designed to assessQOL in breast cancer along the dimensions
of functional well-being, physical well-being, emotional well-
being, and breast cancer-specific factors. The instrument has
demonstrated good validity and reliability in a variety of
studies among women with breast cancer [18, 19].
Depressive symptoms are commonly measured in peo-
ple with cancer by the Center for Epidemiological Studies-
Depression (CES-D) scale [20]. The CES-D is a 20-item scale
that asks participants to report the extent to which they
experienced each of the symptoms in the precedingweek.The
CES-D has been widely used in persons with breast cancer
with alpha coefficient of .88, test-retest reliability .51–.67,
and convergent validity established by significant correlations
with other established measures of depression [6, 21, 22].
2.1.2. Neuroendocrine Measures. Endorphins and enkephal-
ins also are stress-related neuroendocrine mediators, but
little clinical or biobehavioral research examining these
endogenous opioids has yet been conducted. However, there
is mounting evidence that opioid peptides, which are widely
distributed throughout the central, peripheral, and auto-
nomic nervous systems as well as multiple endocrine and
target tissues, downregulate neuroendocrine and autonomic
stress responses [6]. Opioids have been shown to affect in
vitro function of virtually all cells of the immune system
and generally have dose-dependent effects such that low
doses enhance and high doses suppress immune function.
Endorphins and enkephalins also are stress-related neuroen-
docrinemediators, but little clinical or biobehavioral research
examining these endogenous opioids has yet been conducted
[24, 25]. Given the available evidence and increasing interest
in positive stress responses, quantification of opioid peptides
is indicated in clinical studies to begin to explore their
potential roles in neuroendocrine mediation of the stress
process. Participants were provided with a styrofoam ice
chest in order to keep their urine specimens on ice for
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12-hour overnight collection periods. Urine samples were
cryopreserved and batch-assayed for levels of beta-endorphin
and leu-enkephalin using commercial, standardized enzyme-
linked immunosorbent assay (ELISA) kits (MD Biosciences)
according to the manufacturer’s protocols.
2.1.3. Immunological Measures. The role of cytokines, parti-
cularly the proinflammatory cytokines involved in acute
phase responses (IL-1, IL-6, and TNF-𝛼), has been of consi-
derable interest in recent research on psychobehavioral chan-
ges, commonly termed as “sickness behaviors” and including
fatigue and depressed mood, in persons with cancer [26, 27].
Using Bio-Plex Pro (Bio-Rad Inc.)magnetic bead technology,
levels of a standardized panel of cytokines, chemokines, and
growth factors in cryopreserved plasma samples were
analyzed using well-established protocols. The Bio-Rad 17-
plex panel was used to measure IL-1𝛽, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17, granulocyte colony
stimulating factor (G-CSF), granulocyte-macrophage-
(GM-) CSF, IFN-𝛾, monocyte-chemotactic-protein-1 (MCP-
1) (MCAF), macrophage-inflammatory-protein (MIP-) 1𝛽,
and tumor-necrosis-factor-alpha (TNF-𝛼).
2.2. Interventions. Intervention groups met for 90 minutes
each week for a total of 10 weeks. Participants were required
to attend a minimum of 8 sessions to remain in the study.
Based on prior research and in consideration of the potential
physical limitations of our participants, a focused short
form of tai chi training (TCHI) involving eight movements
was used in this study [28]. The sequence of movements
was focused on developing each individual’s skills in bal-
ancing, focused breathing, gentle physical posturing and
movement, and the active use of consciousness for relax-
ation. Movements were taught in a sequence that allowed
repetitive instruction as well as a progressive building of
skills. Training was designed to promote increased control of
attention, increased flexibility, and an integrated mind-body
relaxation experience. Additionally, the particular meanings
and metaphors associated with the TCHI movements were
integrated to provide a cognitive component to enhance
stress management. For example, when teaching the “5 Ele-
ments,” the concepts of ongoing change and transformation
are discussed as represented by the seasons of the year,
and the 5 elements as wood are transformed by fire into
earth, the earth gives rise to minerals, minerals become
water, and water nourishes wood completing the supporting
cycle of life. Training videotapes/DVDs were produced and
distributed to participants for weekly and ongoing practice of
the techniques. To quantify TCHI practice between sessions,
weekly practice cards were distributed; however, the limited
number of cards returned prevented valid assessment of the
amount of practice between sessions. Additionally, while
not quantifiable, participants consistently reported using and
enjoying the TCHI DVDs.
The spiritual growth groups (SPRT) [29] were designed
for personal exploration and group sharing of spirituality,
aimed at enhancing awareness of themeaning and expression
of spirituality while supporting both secular and religious
views of spirituality in a group format. Each session was
designed to explore an aspect of spirituality, including the
intellectual process of knowing or apprehending spirituality;
the experiential component of interconnecting one’s spirit
with self, others, nature, God, or a higher power; and an
appreciation of the multisensory experience of spirituality.
2.3. Data Analytic Approaches. We used mixed linear mod-
eling to compare changes in the usual care control group
with each intervention group and to accommodate for the
correlated structure in the repeated measures for three time
periods (Pre-Ix to Post-Ix, Pre-Ix to F/U 1, and Pre-Ix to
F/U 2). In an attempt to satisfy the model assumptions, the
cytokines were log transformed using loge (natural log). No
effects for potential cofactors such as age, race, menopausal
status, type of therapy, and stage of disease were found in the
initial modeling, and thus they were removed from the final
models.
3. Results
The sample consisted of 145 women aged 27–75 years
(average = 50 years); 75% were Caucasian and 25% African
American. A total of 109 participants completed the inter-
vention or comparable usual care control group measures,
yielding a 75% retention rate. The predominant reason for
attrition, involving a full 40% of withdrawals, was related
to intervention group meetings (i.e., not being able or not
wanting to continue group meetings). No differences were
seen in the demographics for those who withdrew and those
who remained in the study.
Intervention and usual care control group participants
did not differ by age, race, menopausal status, diagnostic
stage, or treatment approach nor by self-reported physical or
functional well-being. Additionally, group participants were
comparably distributed across breast cancer stage. Partici-
pants received relatively consistent protocols for chemother-
apy regimens, guided by national standards and ongoing clin-
ical trials at a National Cancer Institute-designated Cancer
Center or its affiliated local institutions. Following surgical
removal of their breast tumors, the majority of participants
received regimens of cyclophosphamide and doxorubicin
every 2-3 weeks for a total of 4 doses.
For all participants, levels of stress were highest at
baseline, decreased over the period of chemotherapy, and
then plateaued over the recovery period. Similarly, QOL
scores decreased during chemotherapy but increased by the
first follow-up time point. Figure 2 illustrates this type of
pattern with the IES scores, while Table 1 displays the total
sample scores for the IES and FACT-B over time, none
of which were different by group. However, immediately
following postintervention, TCHI participants demonstrated
an increase (𝑃 = 0.003) in depressive symptoms (mean =
15.4, SE = 1.4) as compared to the standard care (mean =
9.2, SE = 1.8) and SPRT (mean = 10.1, SE = 2.2) groups.
This pattern was not evident 6 weeks later at F/U 1, and levels
of depressive symptoms declined for all groups of participants
over time (Figure 3).
Significant elevations were seen in urinary beta-
endorphin levels for the SPRT group immediately following
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Figure 2: Perceived stress scores (IES) for groups over time.
Table 1: Psychological well-being and quality of life: means (SE) for
total sample over time.
Measure Time
Pre-Ix Post-Ix F/U 1 F/U 2
IES∗ 16.92 (0.69) 13.75 (0.72) 12.85 (0.78) 12.63 (0.80)
FACT-B† 105.19 (2.03) 102.96 (2.12) 110.19 (2.20) 110.63 (2.27)
∗Means are significantly different over time (𝑃 < 0.0001) with Pre-Ix mean
significantly greater than Post-Ix, F/U 1, and F/U 2 means.
†Means are significantly different over time (𝑃 < 0.0001) with Pre-Ix and
Post-Ix means significantly greater than F/U 1 and F/U 2 means.
intervention and for both SPRT and TCHI at the 4.5-month
followup (Figure 4). There were no significant differences
in enkephalin levels between groups at any measured time
point.
As displayed in Figure 5 for IL-1𝛽, trends of declining
levels during chemotherapy, followed by recovery of cytokine
levels, were seen for several proinflammatory cytokines (IL-
1𝛽, IL-2, IL-6, and IFN-𝛾). However, the only significant
differences between the two treatment groups and the usual
care control group in the cytokines were seen in IFN-𝛾. As
shown in Figure 6, significant elevations in IFN-𝛾were noted
for both intervention groups at the 6-month followup pos-
sibly reflecting better recovery of proinflammatory cytokine
production.
4. Discussion and Conclusions
The increase in the stress levels in TCHI participants demon-
strated at postintervention when compared to the usual
care control group might be an indication of increased
self-awareness and/or “centering,” reflected as psychological
distress. TCHI, like other mindfulness-based interventions,
focuses on enhancingmindfulness and self-awareness, which
may temporarily increase depressive-like symptoms in the
face of critical illness situations such as cancer chemotherapy.
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Factors such as self-awareness and mindfulness, however,
were not directly measured in this study. Additionally, TCHI
groups were small, typically 3–5 women, and participants
voiced discomfort related to learning a new skill in small
groups. Chintamani and colleagues [10] found that response
to chemotherapy was the most significant variable affect-
ing psychological status in 84 Indian women with locally
advanced breast cancer. While sample size, cultural factors,
and stage of disease limit generalizability of these findings, it
is reasonable to assume that response to treatment impacts
psychological status in women with breast cancer. In the
current study, we did not specifically track response to
treatment and thus could not examine whether this was a
factor contributing to study outcomes.
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Limited studies of traditional stress management inter-
ventions, particularly cognitive behavioral stress manage-
ment (CBSM), have been found to enhance some aspects
of psychosocial and physiological function in women newly
diagnosed with breast cancer. For example, Antoni and
colleagues [30] found that a 10-week CBSM intervention in
a sample of 128 women reduced cancer-specific anxiety and
promoted physiological adaptation as evidenced by reduced
cortisol and increased IL-2, IFN-𝛾, and IL-2:IL-4 ratio.
Additionally, the intervention was associated with increases
in participants’ perceived ability to relax as well as reductions
in afternoon cortisol levels during and immediately following
treatment [27].
CBSM offers a variety of techniques for inducing relax-
ation and cognitively restructuring perceptions of and
responses to stress, thereby enabling participants to choose
the method that works best for them. While the TCHI
intervention offered a variety of different movements, the
combination of movements is consistent with the strength
of traditional TCHI practice, and selection of individual
movements is not encouraged. The SPRT intervention also
offered several activities; however, each activity was focused
on the exploration of one’s spirituality and not necessarily
congruent with inducing relaxation per se. Indeed, such
interventions as TCHI and SPRT may lack the “potency” to
overcome the psychological stress and physiological effects of
chemotherapy itself. It may be that interventions requiring
less activity and/or group attendance would have more ther-
apeutic effects in persons receiving chemotherapy treatment
regimens.
While there were significant changes in urinary beta-
endorphin levels, there were no significant findings for leu-
enkephalin. Given the available evidence and increasing
interest in positive stress responses, quantification of endoge-
nous opioid peptides is a promising addition in clinical
studies to begin to explore their potential roles in the stress
process, including immune function.
Generally, the type, timing, and sequencing of stress man-
agement interventions have as yet undefined effects on out-
comes. Findings of this study highlight the complex nature
of biobehavioral interventions in relation to treatment tra-
jectories and potential outcomes. Psychosocial interventions
like TCHI or SPRT may lack sufficient power to overcome
the psychosocial or physiological stress experienced during
the period of treatment with immunosuppressive chemother-
apeutic agents and commonly experienced side effects such as
fatigue and gastrointestinal disturbances.
Because of the inherent complexity in production, mech-
anisms of action, pleotropic effects, and cytokine patterns
rather than levels of production of one or a selected few
“representative” cytokines need to be evaluated. State-of-the-
science technologies and emerging analytic approaches to
evaluate patterns of cytokines are now being used to dis-
cern clinically meaningful effects and potential mechanistic
insights [22, 31].
Most of the research on psychosocial interventions in
breast cancer involves patients who have completed the active
treatment. Ours is one of few reports of psychosocial inter-
ventions involving movement and spirituality for individuals
during the period of active chemotherapy and/or radiother-
apy for cancer.We undertook a “high-risk” study with respect
to the delivery of somewhat novel interventions during a
period of high stress and complex physical symptoms related
to breast cancer and its treatment. While informal subjec-
tive feedback from participants was positive among most
women who completed the interventions, the quantitative
measures indicated little effect of either intervention in this
study.
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